Cryoglobulinemic Vasculitis
Conditions
Keywords
Cryoglobulinemic vasculitis requiring rituximab therapy
Brief summary
Initial worsening following initiation of rituximab therapy in patients with cryoglobulinemic vasculitis was described in 3.6% of cases. This worsening is often a serious condition, with high levels of mortality. The objective of our study is to evaluate the efficacy of preventive plasmapheresis prior to the introduction of rituximab performed in Montpellier France since 2013 by assessing the frequency and severity of this flare effect in these patients compared to those reported in the literature.
Interventions
None listed
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* cryoglobulinemic vasculitis requiring rituximab treatment * Patient ≥18 years old
Exclusion criteria
* Patient who reject the study protocol * Patient \< 18 years old
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| comparison of frequency of occurrence of flare effects | 1 day | comparison of frequency of occurrence of flare effects between patients who received plasmapheresis prior to rituximab compared to patients who did not. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evaluation of the severity of the flare effect | 1 day | evaluation of the severity of the flare effect |
| impact of known risk factors | 1 day | investigation of the impact of known risk factors for this effect |
| evaluation of the safety of plasmapheresis in this indication | 1 day | evaluation of the safety of plasmapheresis in this indication |
| evaluation of the efficacy of plasmapheresis on biological parameters | 1 day | evaluation of the efficacy of plasmapheresis on biological parameters |
Countries
France
Contacts
Primary ContactCharles HERBAUX, assistant Professor
Outcome results
None listed